On the flip side this is causing usage on current installs to escalate. If there were more units out there, the volume would be spread out.
Curious to any long holders on this board but was this stock originally priced on the expectations that a high # of units would be sold? What is the margin like on a unit install?
And the compare this to the recurring margins for all of the procedures. I know it doesn't come close, but still its "growth" in a certain kind of way.
A long term owner if that allows me to qualify for a reply. For an interesting case study one can search Stereotaxis Michigan to find there are 3 Michigan hospitals and universities employing the technology. Then go state to state to find other users. All are reporting good results. Why the StXS web site does not give more information is a wonder.
With another positive quarter STXS may finally hit that sweet spot and go to $3.00 for starters
Agree Sting.. we need more news.. We should at least be selling at one times revenues per share of $1.79.. for many starting out companies in this area $1.79 would be considered very good.
inventory i used in the context of the two FDA news (US and Japan)...not finished goods inventory (although they did ramp up substantially for Q4)...the FDA news they received well before xmas (Japan FDA too)....PR however was January....
regarding profit...a pps of 1.50 at 31st december will result in a profit of app mil$3 (additional mil$+1 compared to Q3) because of their warrant liabilty in the books..for a company that reports non gaap it has no impact, but stxs does not report non gaap....
as such expect the headline "stxs reports Q4 profit of mil $2 in Q4".
google the Q3 headline:
"Stereotaxis posts Q3 profit", "reported a third-quarter profit of $22,670"...For Q4 it should be millions if system revenue is stable....
btw, start to get familiar with the post from jaspr4 in that thread...see below, ablation history...should be adressed this week
Sentiment: Strong Buy
currently it is basically a pig with a supernice lipstick on it.....
"I suspect when this gets proper respect"
infact stxs has a disconnect regarding proper respect...proper, even maximum possible respect they have in the medical space as such being the ultimate powerhouse with basically no competion...you won`t find any negative article on product or market for that powerhouse....there is a reason why they own the space worldwide....hard, almost impossible, to find a company with that market share in any industry
in total contrast you have the disrespect from WS...for WS stxs does not exist currently....imo, investor relations is poor....i hope with the recent PR´s they start to close that gap...anyway that gap will be closed irrespective....
take russia as one on many examples.....russia is one of the top emerging markets for EP...stxs is alone in russia, monopolist, nobody else is there....the recent installed system has currently the highest utilization of all installed stxs systems worldwide...who knows these things?..nobody, because you basically have to be an insider to know it...examples are endless...imo that is a mangement issue..let´s see how they adress that...imo it is very easy to fix it...they just need to start to communicate with WS
It's just a matter of time. Here is another excellent report that didn't make the news wires:
it's been a sinking ship for quite a few years. It needs sales, badly, and it can't keep sales people because no hospitals want to put that much money into a system with this economic climate in the medical industry.
How long have you been on this ride? I've thrown up many times and still have managed to stay on this boat.
Another great article about STXS in the current issue of EP Lab Digest (Volume 15 – Issue 1 – January 2015). Excerpts below. They are certainly getting good PR here! The clinical evidence in support of STXS systems is very positive. I expect this will eventually translate into increased sales and utilization.
A 21-year-old male college student was referred for management of recurrent palpitations and near syncope…. Because of the issues with catheter stability encountered at the first procedure, we elected to use the Stereotaxis Niobe ES system for the repeat procedure….
Catheter ablation of Mahaim-type accessory pathways can be difficult due to challenges with accurate mapping of AP location. Conventional mapping and ablation techniques were used on the initial attempt, but technical issues rather than mapping or diagnostic ones ultimately hampered success. Non-fluoroscopic 3D mapping proved valuable for tagging pathway location, and the flexible nature of the Stereotaxis ablation catheter permitted stable catheter position against the endocardium with adequate energy delivery despite significant cardiac and respiratory motion.
Sentiment: Strong Buy
The rollout of Ablation History is another wildcard that might also have a positive affect on utilization in 4Q. It was mentioned as a powerful tool and shortened procedure times in the Palm Springs article in EP Lab Digest. And in the Dr. Peter Weiss video on the company website, he says that ablation history gives the Stereotaxis system control of the 3 legs to the stool – contact force, power, and time. Whereas manual catheters only allow for the control of time, and contact force catheters only give control over contact force and time.
I liked your line,". . . bottom range in an obscure stock that has a low float and will do fine for 2015." The part about doing fine for 2015 is probably the key to raising the curtain on this thing and seeing its stardom come into view. It's been a frustrating stock to own, always so close and yet so far; so far, that is! Better times ahead! :)
Numbers are expected to be good. May even show a profitable quarter sometime this year. I think that would be the first one.